Literature DB >> 20112092

Limited-stage small cell lung cancer: local failure after concurrent chemoradiotherapy with use of accelerated hyperfractionation.

Takuhito Tada1, Masako Hosono, Yoshie Takada, Shinzo Kudoh, Kentaro Ishii, Ryo Ogino, Shinichi Tsutsumi.   

Abstract

PURPOSE: The aim of this study was to update data of radiation therapy regimens for improvement in local control in patients with limited-stage small cell lung cancer, a retrospective study was conducted.
MATERIALS AND METHODS: Results of early concurrent chemoradiotherapy with accelerated hyperfractionation in 30 patients between 1998 and 2005 were retrospectively reviewed. The prescribed dose was 45 Gy in 30 fractions in all patients.
RESULTS: All patients received a full dose of radiation therapy; however, interruptions for >or=5 days, mainly due to hematologic toxicity, were required in 18 patients (60%). The 5-year Kaplan-Meier survival rate and the median survival time were 26% and 26 months, respectively. The 4-year in-field control rate was 56%. Sites of relapse were local relapse in 9 patients (6 for in-field relapse, 3 for marginal relapse) and distant metastases in 16 patients (11 for distant metastases only, 5 for distant metastases with local relapse). The sites of marginal relapse were the upper margin in two patients and the peripheral margin in one patient. Grade 3 radiation esophagitis was observed in only three patients.
CONCLUSION: Because in-field control was insufficient, a more effective approach should be sought to provide better local control.

Entities:  

Mesh:

Year:  2010        PMID: 20112092     DOI: 10.1007/s11604-009-0383-7

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  12 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors:  J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

3.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

Authors:  A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

4.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

5.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Authors:  Jeffrey Bradley; Mary V Graham; Kathryn Winter; James A Purdy; Ritsuko Komaki; Wilson H Roa; Janice K Ryu; Walter Bosch; Bahman Emami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

6.  Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.

Authors:  Dirk De Ruysscher; Stofferinus Wanders; Erik van Haren; Monique Hochstenbag; Wiel Geeraedts; Irwan Utama; Jean Simons; Jo Dohmen; Ali Rhami; Ulrich Buell; Paul Thimister; Gabriel Snoep; Liesbeth Boersma; Tom Verschueren; Angela van Baardwijk; Andre Minken; Søren M Bentzen; Philippe Lambin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

7.  Changes in patterns of care for limited-stage small-cell lung cancer: results of the 99-01 patterns of care study-a nationwide survey in Japan.

Authors:  Takashi Uno; Minako Sumi; Yoshitomo Ishihara; Hodaka Numasaki; Michihide Mitsumori; Teruki Teshima
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

8.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.

Authors:  J D Cox; T F Pajak; S Asbell; A H Russell; J Pederson; R W Byhardt; B Emami; M Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-10-20       Impact factor: 7.038

9.  Limited-stage small cell lung cancer: local failure after chemotherapy and radiation therapy.

Authors:  T Tada; K Minakuchi; M Koda; N Masuda; K Matsui; I Kawase; T Nakajima; M Nishioka; M Fukuoka; T Kozuka
Journal:  Radiology       Date:  1998-08       Impact factor: 11.105

10.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

Authors:  Minoru Takada; Masahiro Fukuoka; Masaaki Kawahara; Takahiko Sugiura; Akira Yokoyama; Soichiro Yokota; Yutaka Nishiwaki; Koshiro Watanabe; Kazumasa Noda; Tomohide Tamura; Haruhiko Fukuda; Nagahiro Saijo
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

View more
  2 in total

1.  Magnetic resonance (MR) imaging for tumor staging and definition of tumor volumes on radiation treatment planning in nonsmall cell lung cancer: A prospective radiographic cohort study of single center clinical outcome.

Authors:  Dan Zhao; Qiaoqiao Hu; Liping Qi; Juan Wang; Hao Wu; Guangying Zhu; Huiming Yu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

Review 2.  Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.

Authors:  Sukhvinder Johal; Robert Hettle; Joe Carroll; Peter Maguire; Tammy Wynne
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.